Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Debt / NOTE 2.250% 3/0
-
Market price (% of par)
-
63.47%
-
Total 13F principal
-
$273,167,017
-
Principal change
-
-$61,027,983
-
Total reported market value
-
$213,304,940
-
Number of holders
-
18
-
Value change
-
-$34,118,990,829
-
Number of buys
-
7
-
Number of sells
-
7
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q1 2024
As of 31 Mar 2024,
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by
18 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$273,167,017
in principal (par value) of the bond.
The largest 10 bondholders included
WOLVERINE ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., HIGHBRIDGE CAPITAL MANAGEMENT LLC, LAZARD ASSET MANAGEMENT LLC, OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC), AVIVA PLC, CITIGROUP INC, CAPSTONE INVESTMENT ADVISORS, LLC, SILVERBACK ASSET MANAGEMENT LLC, and AQR Arbitrage LLC.
This page lists
18
institutional bondholders reporting positions
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.